Global Cardiovascular Innovation Center Incubator Program

Accord Biosciences focuses upon biomarker assays and diagnostic tools targeting s-nitrosothiols (RSNOs) to asses disease states in which pathways involving nitric oxide (NO) and its physiologic carrier RSNO are implicated. Accord is initiating clinical trials in Q3 2010 for the company’s lead program in pulmonary hypertension. For more information contact Kris Aalto via email at mail to: kaalto@accordbiosciences.com or (734) 995-9089 x229.

They are developing a Left Ventricular Assist System intended to provide long-term mechanical circulatory support for patients with terminal heart failure who are unresponsive to conventional therapies.  For more information, contact Franz Kellar via email at fkellar@clevelandheart.com. Or visit www.clevelandheart.com.

Creganna-Tactx Medical is a leading supplier of products, technologies and services to medical device and lifescience companies worldwide. The company specializes in the design and manufacture of minimally invasive therapy and diagnostic devices for coronary, peripheral vascular, neuro vascular and GI therapies. Headquartered in Galway, Ireland, Creganna-Tactx Medical employs over 1,000 people worldwide and has design and manufacturing operations in the US (CA, MN & MA) and Asia (Singapore, Korea).  For more information visit: http://www.cregannatactx.com or contact scott.olson@creganna.com.

Explorys formed a partnership with Cleveland Clinic, Explorys addresses the national imperative to leverage electronic health records (EHR) for the improvement of medicine. Our networked platform enables the discovery of critical correlations, trends, and outcomes across millions of patients, clinical records, and diverse environments — providing unique insight to enable providers and life sciences organization to deliver safer, more efficient and more effective healthcare. This capability creates new opportunities for healthcare providers and life sciences organizations to partner, collaborate, and identify breakthroughs in safety, innovation, and efficiency in the delivery of care.

Farm is a full-service, ISO 13485-certified and FDA-compliant product development company celebrating 40 years of experience providing complete development and regulatory services for medical, life sciences, and consumer health companies. Our services include User Research, Human Factors Engineering, User Interface Design, Industrial Design, Systems Engineering (Mechanical, Electrical, Software), Usability Testing, Pilot Production, and Regulatory Compliance.

genae is an innovative services provider for the medical industries. The development and marketing of medical devices and therapies in today’s global marketplace is a highly regulated process with strict requirements from many competent authorities. genae is a catalyst between the health care authorities, investigators in clinical practice and the medical industry to set up and support development processes. We communicate with civil servants in ministries of health, regional and local healthcare authorities, healthcare associations, healthcare technology assessment bodies, health insurance funds and other relevant parties. genae’s ultimate objective is to support the medical industry in obtaining product approval and in achieving a marketable product and market acceptance, in a timely and cost-effective way, while meeting or exceeding all relevant quality standards.

Global Clinical Connections is involved in total Supply Chain Management. Services range from API (active pharmaceutical ingredient) production through drug manufacturing, packaging, labeling of supplies, and worldwide distribution of Phase I-IV trial supplies to clinical sites. Global Clinical Connections coordinates all or part of the process, monitors progress, and provides updates toward milestones for contracted activities at the vendors. 

IceCure Medical, Inc. develops and commercializes cryoablative treatments for applications in women’s health.  Our first technology, IceSense3, offers a minimally invasive, in-office procedure for the treatment of symptomatic breast fibroadenoma.  IceSense3 is an attractive alternative to the current standard treatment of open surgical excision.  The IceSense3 probe is inserted under ultrasound guidance while the system uses liquid nitrogen for rapid freezing. Our advanced cryoablation probe design provides a treatment zone that is easily customized to match the size and shape of the targeted fibroadenoma. The IceSense3 cryoablation is a viable treatment option because it is safe and effective and can be performed in as little as 5 minutes.  Physicians are pleased with the system because the learning curve is short and patient satisfaction is high. Patients are pleased with the cosmetically superior results that can be achieved with minimal discomfort in an office setting. For more information, please contact us at (888)516-7389 or visit our website at www.icecure-medical.com.

ImageIQ provides expertise in the incorporation of advanced image acquisition, processing, analysis and visualization into the research and development of biotechnologies. Serving the research, medical device, pharmaceutical and legal markets, ImageIQ has helped improve the effectiveness of R&D, product development, regulatory approval and product liability litigation through the use of their customizable software platforms and unique imaging-based approach to solving biomedical problems. ImageIQ also works with scientists and clinicians throughout the world to develop novel medical technologies ranging preoperative surgical planning software to image-based diagnostics for detecting the early onset of hypertension and diabetes. For more information, please contact Tim Kulbago: tkulbago@imgiq.com.

Juventas Therapeutics is developing a pipeline of regenerative therapies to treat life-threatening diseases. The company’s lead product, Stromal-cell Derived Factor 1 (SDF-1), has been shown to protect and repair tissue following organ-damage in a broad range of pre-clincial disease models. In addition, Juventas is developing SDF-1 into a platform therapy with active development programs in peripheral vascular disease and wound healing.

PediaWorks and Medikit agreed that children should have access to the same medical advancements as adults, but very few pediatric products were actually reaching the market.  So in 2009 they partnered to form PediaCath, the first and only organization to develop catheters just for children.  PediaCath leverages Medikit’s experienced team of R&D engineers and rapid prototyping facilities, and PediaWorks access to a broad network of pediatric clinical advisors and research partners.  PediaCath’s initial focus is on catheters used by cardiologists. For more information contact Tim Moran via tim@pediacath.com.

Peritec Bioscience is developing a hybrid solution which uses biology in combination with stents in a way which vastly reduces the likelihood of the adverse reactions that accompany other stents. Also, optimal blood flow is assured in specifically designed stents.

Renovo Neural is a drug discovery company involved in development of proprietary small molecule pharmaceutical candidates that can provide complementary therapeutics for neuro-immunomodulation market. In addition, Renovo is creating a niche of specialty services that can revolutionize development of therapies for neural diseases, specifically multiple sclerosis.

SDG, Inc. was formed in 1993 to develop its proprietary nanotechnology-based drug and diagnostics delivery systems. SDG has spun-out several therapeutic specific companies, including Diasome Pharmaceuticals, Inc. a venture-backed company focused on hepatic specific oral and injectable insulin therapies. SW’s technology pipeline includes active programs in oral protein delivery, diabetes, metabolic/obesity, cancer diagnostics, and hepatitis. For more information, please email Bob Geho at bob@sdgpharma.com.

Securus Medical Group is developing clinical tools to monitor core body temperature within body cavities. Thermal injury to the tissue due to energy from various sources can create damage to surrounding tissue. Securus will provide clinicians a simple to use, real-time, noncontact, thermal map of body cavity tissue temperature. This information will guide the physician to achieve the desired clinical outcome without risk of injury to surrounding tissue. For more information, please contact Donna Richardson at drichardson@securusmg.com.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote wound repair and prevent scarring of dermal wounds.  Our lead product, SRX-100 is a clinically tested product that encodes Stromal cell-Derived Factor-1 (SDF-1).  SDF-1 is produced by the body in response to tissue injury and activates natural repair processes to prevent cell death and recruit stem cells to the damaged organ.

SIFT-MS is an analytical technology ideally suited to analysis of air samples for volatile organic compounds (VOCs). Its unique multiple reagent ion system delivers results not possible with other real-time techniques. At Syft Technologies we have taken research-based SIFT-MS and developed it into commercially-viable, user friendly analytical instrumentation that provides solutions to a diverse range of applications and markets.

Focused on the clinical implementation of cardiovascular molecular diagnostics the company has a principal interest in pharmacogenomics but is also involved in wider activities around the field of personalized medicine. Our mission is to improve patient care by matching the right treatment to the right patient. They believe this will reduce healthcare costs through the sustainable adoption of new treatments.

TheraVasc Inc. (TheraVasc or “the Company”) is a privately-held biotechnology C-Corp located in Ohio dedicated to reducing the risk, cost and time associated with drug development by focusing on developing repurposed drugs for unserved vascular disease markets. By focusing its efforts on drugs with established safety profiles, targeting diseases that result in a terrible quality of life or rapidly progress to death, and for which no current therapies exist, TheraVasc’s management believes that both patients and clinicians will readily embrace its products, facilitating development. The Company’s first program is ready to enter clinical trials for the treatment of peripheral artery disease (PAD) and other problems associated with poor blood flow to the limbs, including diabetic vascular disease (DVD).

Based in Cleveland and built on technology developed by Dr. Michael A. Weiss at Case Western Reserve Medical School, Thermalin Diabetes, LLC is developing clinically-superior, second generation, insulin analogs for the rapidly-growing $12 billion insulin market. Themalin’s patent pending compounds include rapid-, intermediate – and long-acting analogs. For more information, please contact Richard Berenson(rick@thermlin.com).

TransWorld Med Corporation was formed with the medical objective of dramatically improving the quality of life through innovative technology. Significant reduction in patient mortality will be achieved by the company’s patented devices and algorithms. The noninvasive techniques and monitoring methodologies will be extremely useful in preventing hospitalizations and adverse outcomes associated with the painful biopsies currently utilized by the medical industry for these patients. TransWorld Med will facilitate the lowering of health costs for patients while appreciably improving their quality of life. This device and technology will therefore be easily embraced by physicians, insurance companies, and governmental third party payers. Extension of these medical technologies into other chronic disease processes will have a similar economic cost savings impact.